面向临床药物研发的AI成功率分析平台

Unlearn.AI builds AI-generated digital twins of clinical trial participants — forecasts of how each individual patient's outcomes would evolve — and uses them to sharpen design, interim, and readout decisions in drug development.
网站月访问量估算
数据为该域名的 Similarweb 流量估算,不是活跃用户数。仅展示有数据的统计月份;采集时间与流量统计月份分别标注。
采集于 2026年11月11日

这是编辑给出的评估,满分 5 分,不是用户打分的平均值。 本页的各方观点由 AI 根据产品信息归纳,不是真实用户的评价。
根据 OpenAITools.app 于 2026-11-11 核对的流量数据,Unlearn.AI(unlearn.ai)是一个收录在 AI 医疗健康下的 AI 平台,月访问量为 1.71万,月度环比流量变化为 -8233(-32.5%)。其主要地理市场为美国(69.4% 流量份额),采用定价请咨询定价模式。按月流量计算的主要竞争替代方案包括 Intelligencia AI(3872 次访问/月),Cradle(1.7万次访问/月),Floatz(253 次访问/月)。
数字孪生做对照组绝了,三期临床直接省了大把时间和病人招募成本。
药企合规审批利器,就是门槛太高。
神仙技术。
牛逼。
以下短评基于实时网页探查、定价机制与同类产品基准由 AI 综合模拟生成,旨在呈现不同使用场景下的常见槽点与亮点,非实名真实用户评价。
Model-based forecasts of each participant's clinical outcomes, generated from baseline data already collected, that act as a virtual comparator or as additional information per enrolled patient.
A twin-based covariate adjustment approach that Unlearn describes as EMA-qualified and FDA-supported, used to reduce sample size in randomized controlled trials while maintaining power.
Build and compare design scenarios — endpoints, eligibility criteria, sample size, assumptions — so governance decisions are made with quantified tradeoffs instead of positions.
Pre-specified twin-based analyses added to the statistical analysis plan before unblinding, plus twin-adjusted analysis delivered at interim and at readout.
Design single-arm and externally controlled studies where randomization is not an option, selecting eligibility criteria that give open-label studies the best chance of a clear readout.
Unlearn.AI builds AI-generated digital twins of clinical trial participants — forecasts of how each individual patient's outcomes would evolve — and uses them to sharpen design, interim, and readout decisions in drug development.
Simulate expected enrollees against real eligibility criteria, then evaluate sample size and endpoints to lock in a smaller, lower-cost design before governance review.
Raise power at interim looks and in subgroup analyses without adding participants by incorporating twin-based covariate adjustment into the statistical analysis plan.
Re-analyze finished studies with digital twins to contextualize variability, improve endpoint sensitivity, and inform whether and how the program continues.
Use digital twins as the comparator in open-label or single-arm studies where randomization is impractical, tightening the evidence for regulators.
同一分类下同类 AI 工具的流量并排对比
| 排名 | AI 工具 | 月访问量 | 月度环比增长 | 直接流量占比 | 定价 | 头对头 |
|---|---|---|---|---|---|---|
| ● | Unlearn.AI | 1.71万 | -32.5% | 44% 直接流量 | 定价请咨询 | 当前产品 |
| 1 | Intelligencia AI | 3872 | -31.9% | 27% 直接流量 | 定价请咨询 | 对比 Intelligencia AI |
| 2 | Cradle | 1.7万 | -22.3% | 37% 直接流量 | 定价请咨询 | 对比 Cradle |
| 3 | Floatz | 253 | -36.8% | 37% 直接流量 | 定价请咨询 | 对比 Floatz |
| 4 | Delve AI | 4.9万 | -4.6% | 40% 直接流量 | 免费增值 | 对比 Delve AI |
| 5 | Dr.Oracle | 72.38万 | -1.2% | 12% 直接流量 | 免费试用 | 对比 Dr.Oracle |
| 6 | Aitia(gnshealthcare.com) | 0 | 0% | — | 定价请咨询 | 对比 Aitia(gnshealthcare.com) |
面向临床药物研发的AI成功率分析平台
免费 / 开源按需生成有数据支撑的用户画像、数字分身与合成调研
Sinkove generates synthetic biomedical images and anatomy data using AI, giving researchers and healthcare teams privacy-safe visual datasets to accelerate clinical research, model training and virtual trials.
Sinkove generates synthetic biomedical images and anatomy data using AI, giving researchers and healthcare teams privacy-safe visual datasets to accelerate clinical research, model training and virtual trials.
用 AI 找到符合筛查条件的患者,并为每个肺结节打风险分
免费 / 开源用数字孪生社会仿真优化广告与受众洞察
免费 / 开源面向营养与代谢数据的健康智能基础设施